Abstract:Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin9s B-cell lymphoma and represents 4% to 8% of NHL. New therapeutic strategies are under development to improve the clinical outcome of patients with this disease. Recent studies have highlighted the importance of BRD/acetyl-lysine binding in orchestrating molecular interactions in chromatin biology and regulating gene transcription. The Bromodomain (BRD) is a diverse family of evolutionary conserved protein-interaction modules, which recognizes acetylated lysine residues such as those on the N-terminal tails of histones. We have recently determined the functional consequences of inhibiting Bromodomains in MCL. First, we evaluated the effects of JQ1, a selective small-molecule bromodomain inhibitor upon MCL9s immunogenicity and antigen-specific CD4 + T-cell responses. In vitro treatment of MCL cells with increasing concentrations of JQ1 resulted in a decreased expression of the tolerogenic molecule PD-L1 as compared to control cells. Second, we evaluated the capabilities of JQ1-treated MCL cells to present cognate antigen to naive or anergic antigen-specific CD4 + T-cells. We found that treatment of MCL cells with JQ1 enhances their antigen-presenting capabilities leading to effective priming of naive CD4 + T-cells and restoring the responsiveness of tolerant T-cells as determined by their increased production of IL-2 and IFN-gamma in response to cognate antigen. More importantly, in vivo studies clearly demonstrated a strong anti-tumor effect in JQ1-treated MCL tumor bearing mice. Mechanistically, we found a decreased STAT3 phosphorylation and c-Myc expression in JQ1-treated MCL cells, which in turn might be responsible for the diminished expression of PDL1 and augmentation of MCL9s immunogenicity. Taken together, we have found that MCL cells treated with the Bromodomain specific inhibitor JQ1 are more inflammatory, display lower expression of the immunosuppressive molecule PDL1 and, are capable of restoring the responsiveness of tolerant T-cells. More importantly, JQ1 treatment in vivo inhibits tumor growth in MCL tumor bearing animals. Our studies therefore have unveiled a previously unknown immunological effect of BRD inhibitors and have identified a novel immunotherapeutic approach in MCL. Disclosures No relevant conflicts of interest to declare.

JQ1: a novel potential therapeutic target.

Targeting SIRT1 Synergistically Improves the Antitumor Effect of JQ-1 in Hepatocellular Carcinoma

Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice

BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC

Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy

Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma

JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer*

BET Inhibitor JQ1 Suppresses Cell Proliferation Via Inducing Autophagy and Activating LKB1/AMPK in Bladder Cancer Cells.

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis

BET Bromodomain Inhibition Potentiates Ocular Melanoma Therapy by Inducing Cell Cycle Arrest

JQ1 suppresses cell proliferation and induces apoptosis in bladder cancer

BET Inhibitor JQ1 Selectively Reduce Tregs by Upregulating STAT3 and Suppressing PD-1 Expression in Patients with Multiple Myeloma.

JQ1, a Small Molecule Inhibitor of BRD4, Suppresses Cell Growth and Invasion in Oral Squamous Cell Carcinoma

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer

Jq1, A Selective Bromodomain Inhibitor, Augment The Immunogenicity Of Mantle Cell Lymphoma By Influencing The Expression Of Pd-L1

Inhibition of Bromodomain Regulates Cellular Senescence in Pancreatic Adenocarcinoma

BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction

Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions

BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling